tirzepatide
Incretin receptor agonists · 21 suppliers · $0.48 to $15.50 per mg · 286 registered studies · 2,524 indexed papers
This page holds two records that were compiled separately. The research figures below come from the public registries named under each one, each read on the date printed beside it. The supplier prices at the foot were read on the suppliers own sites on the dates in that table. Nothing here was produced by this publication measuring anything.
Identity and computed properties
PubChem holds this compound as CID 166567236, molecular formula C225H348N48O68, average mass 4813 daltons and monoisotopic mass 4810.5249 daltons, read on 2026-09-19. Those masses are computed from the deposited structure and were not measured on any material, so they are the expected value an identity check compares against rather than evidence about any vial.
The title that record carries for the CID is CID 166567236. Its synonym list runs to 10 entries. Among them: Tirzepatide, Mounjaro (TN), Zepbound (TN), Tirzepatide free base?, Tirzepatide (JAN/USAN) and WLZ4518.
Receptors the literature describes
No published paper this search reached describes a receptor this compound acts at.
The registered trial record
An intervention search of clinicaltrials.gov for the term tirzepatide, read on 2026-09-19, returned 286 registered studies: 6 early phase 1, 38 phase 1, 77 phase 2, 53 phase 3, 46 phase 4 and 76 recorded with no phase.
Eli Lilly and Company is lead sponsor on 80 of the 286 records. The remaining 206 name 154 other organizations.
On the date read, the statuses those records carried were 95 recruiting, 88 completed and 59 not yet recruiting, among others.
The earliest record the search returns is NCT02759107, first submitted 2016-04-29. That date is a floor, not an origin: earlier work may sit in the registry under a code number this search term does not match.
Registry counts measure registration, not knowledge.
The publication record
PubMed answered 2,524 records for the term tirzepatide on 2026-09-19. Of those, 145 carry a clinical-trial publication type, and 66 of those carry Clinical Trial, Phase III. 906 carry the publication type Review, which is other people reading the rest.
PubMed counts measure indexing, so work in venues it does not index is invisible to this figure. The term that produced it is printed above so it can be run again.
Regulatory status
The Drugs@FDA database holds application NDA 217806 under this name, sponsor ELI LILLY AND CO. Its listed products are marked Prescription in the same database.
The Drugs@FDA database holds application NDA 215866 under this name, sponsor ELI LILLY AND CO. Its listed products are marked Prescription in the same database.
Findings, as published reports recorded them
This block was compiled and no finding from a named publication was reached.
Adverse events, as published reports recorded them
This block was compiled and no adverse event from a named publication was reached.
Spontaneous report databases are not used on this page. A count of reports carries no denominator, so it cannot be read as a rate and is not printed as one.
Who it is not given to
labelTwo groups must not be given Mounjaro. Anyone who has had medullary thyroid cancer or whose family has, including anyone with Multiple Endocrine Neoplasia type 2, and anyone who has had a serious allergic reaction to tirzepatide.MOUNJARO label · read 2026-09-19
labelMounjaro carries a boxed warning, the strongest kind. Tirzepatide caused thyroid tumours in male and female rats at doses in the human range. The label says it is not known whether it does the same in people.MOUNJARO label · read 2026-09-19
Mounjaro and Zepbound are prescription medicines made by Eli Lilly. Powder sold as tirzepatide is not either of them.read 2026-09-19
Every row is a price read on that supplier's own site, divided by the milligrams it buys. Cheapest first, which is not a ranking of quality: the columns beside the rate show what this publication could confirm about the evidence behind it. Some supplier links here are referral links, marked where they appear, which pay Terminus Research when a reader buys. The same terms are open to every supplier in the ledger, apart from the one exception the referral policy page names, participation changes no score, rank, caution, or coverage decision, and a link is not an endorsement.
Vendor comparison
| Per mg | Price | Supplier | Certificate checkable | Caution on record | What the figure is |
|---|---|---|---|---|---|
| $0.48per mg | $145.0030mg × 10 vials | reta-peptiderecord → | not transcribed | not transcribed | 10-vial kit, 30mg per vial; listing abbreviates the name to Tirzread 2026-08-20 |
| $0.60per mg | $60.0010mg × 10 vials | Qingdao Sigma Chemicalrecord → | not transcribed | not transcribed | 1 kit (10 vials), 10mg per vialread 2026-08-20 |
| $0.88per mg | $176.0020mg × 10 vials | GreyLabsrecord → | not transcribed | not transcribed | 10-vial kit; mg is the per-vial sizeread 2026-08-25 |
| $1.18per mg | $117.9010mg × 10 vials | GreyLabsrecord → | not transcribed | not transcribed | 10-vial kit; mg is the per-vial sizeread 2026-08-25 |
| $1.57per mg | $31.5020mg | GreyLabsrecord → | not transcribed | not transcribed | single vial, on-hand United States categoryread 2026-08-25 |
| $1.97per mg | $59.0030mg | Virtus Peptidesrecord → | not transcribed | not transcribed | single vial current price; house code GLP-2 (TZ) resolved from the CAS number printed in the same sentence, 2023788-19-2read 2026-08-25 |
| $2.25per mg | $22.5010mg | GreyLabsrecord → | not transcribed | not transcribed | single vial, on-hand United States categoryread 2026-08-25 |
| $2.60per mg | $2599.001000mg | BulkGLPrecord → | not transcribed | not transcribed | single listed unit, current price; house code GLP2-T expanded as tirzepatide in the sentence itselfread 2026-08-26 |
| $3.00per mg | $15.005mg | SCYRXrecord → | not transcribed | not transcribed | single vial current price; sentence states Semaglutide 5mg and Tirzepatide 5mg at $15.00 eachread 2026-08-26 |
| $3.50per mg | $140.0040mg | BulkGLPrecord → | not transcribed | not transcribed | single listed unit, current price; house code GLP2-T expanded as tirzepatide in the sentence itselfread 2026-08-26 |
| $4.00per mg | $120.0030mg | VeraChain Labsrecord → | not checkable | Two conflicting molecular weights appear for one compound, and a 5mg certificate is badged on a 10mg product page. | single vial current priceread 2026-08-24 |
| $4.00per mg | $120.0030mg | Forward Peptidesrecord → | not transcribed | not transcribed | single vial current price; listed as "GLP-2 (Tirzepatide) 30 MG", compound named in the listing itselfread 2026-08-25 |
| $4.00per mg | $240.0060mg | Nextday Peptidesrecord → | not transcribed | not transcribed | single vial current price, sold as GLP2 Tirz, SKU NDP-054; the 246.00 and 366.00 box prices are not recorded because theread 2026-08-26 |
| $5.17per mg | $207.0040mg | Aspire Peptidesrecord → | not transcribed | not transcribed | discounted from 345.00; listed as GLP-1 + GIP (TZ), identified as tirzepatide in the sentence. Receptor targets, not a bread 2026-08-25 |
| $5.50per mg | $55.0010mg | NeuroPept Labsrecord → | not transcribed | not transcribed | single vial current price; house code GLP-TZ expanded as Tirzepatide in the sentenceread 2026-08-26 |
| $5.95per mg | $119.0020mg | Vertex Labsrecord → | not checkable | The address and telephone printed on the certificates do not match those the laboratory publishes on its own contact page. City and ZIP agree, street number, suite and telephone do not. No cause has been established. | single vial current priceread 2026-08-24 |
| $6.30per mg | $125.9920mg | Apollo Peptide Sciencesrecord → | not transcribed | not transcribed | single vial current price; listed as GLP-2 Tread 2026-08-25 |
| $7.00per mg | $70.0010mg | Full Scale Peptidesrecord → | not transcribed | not transcribed | discounted from 80.00; listed as Tirzepatide (GLP-2 TRZ), compound named in the listing itselfread 2026-08-25 |
| $7.33per mg | $109.9915mg | Apollo Peptide Sciencesrecord → | not transcribed | not transcribed | single vial current price; listed as GLP-2 T, named tirzepatide with CAS 2023788-19-2 in the listing itselfread 2026-08-25 |
| $7.74per mg | $77.4010mg | Aspire Peptidesrecord → | not transcribed | not transcribed | discounted from 129.00; listed as GLP-1 + GIP (TZ) and identified as tirzepatide in the sentence. The receptor pair is aread 2026-08-25 |
| $8.00per mg | $80.0010mg | Nextday Peptidesrecord → | not transcribed | not transcribed | single vial current price, sold as GLP2 Tirz, SKU NDP-054, house code expanded as Tirzepatide in the sentenceread 2026-08-26 |
| $9.50per mg | $95.0010mg | ProPeptidesrecord → | not checkable | The certificate page contains no document, no lot, no figure and no laboratory name. | discounted from 130.00 (code resolved by slug /shop/tirzepatide-10mg-vial/)read 2026-08-24 |
| $9.90per mg | $99.0010mg | Improved Peptidesrecord → | not transcribed | not transcribed | single vial current price; GLP-2T expanded as Tirzepatide in the sentenceread 2026-08-26 |
| $12.88per mg | $128.8810.01mg | Modern Aminosrecord → | not transcribed | not transcribed | single vial current price; house code Modern-Trz expanded to Tirzepatide in the sentenceread 2026-08-17 |
| $13.33per mg | $400.0030mg | Grey Research Peptidesrecord → | not transcribed | not transcribed | single vial current priceread 2026-08-25 |
| $14.98per mg | $74.905mg | Evolve Peptidesrecord → | not transcribed | not transcribed | single vial current price (59.92 is the deepest bulk tier, not the single-vial price)read 2026-08-23 |
| $15.00per mg | $149.9910mg | Lab Trust Peptidesrecord → | not transcribed | not transcribed | single vial current price in USD, discounted from 179.99read 2026-08-26 |
| $15.00per mg | $150.0010mg | Grey Research Peptidesrecord → | not transcribed | not transcribed | single vial current priceread 2026-08-25 |
| $15.50per mg | $155.0010mg | Prime Labsrecord → | not transcribed | not transcribed | single vial current price from catalog dataread 2026-08-26 |
Read between 2026-08-17 and 2026-08-26. Prices move and these were read once.
Sources
Registered study counts, phases, lead sponsors and first-submitted dates: the clinicaltrials.gov public API, one intervention search on the term printed above, read 2026-09-19. Indexed paper counts and publication types: PubMed, the term printed above and that term narrowed by publication type, read 2026-09-19. Formula and computed mass: PubChem, the CID printed above, read 2026-09-19. Application status: the Food and Drug Administration Drugs@FDA database through the agency public endpoint, read 2026-09-19.
The dates in the paragraph above are the dates those fetches ran, stamped in UTC. The dates in the list below are the dates a person read each record. The same record can carry both, a day apart, when a fetch ran after midnight UTC.
- PubChem compound record, CID 166567236 read 2026-09-19
- Food and Drug Administration label record, openFDA drug label endpoint, tirzepatide read 2026-09-19